82N-0166
SUP 4
Volumes 22-25

Volume 22

Cover Letter

Reference 1 - Hanston P., Horn P., Salicylates in: Drug Interactions and Updates. Lea & Fabinger, Malvem, PA, 1990, 154- 155.

Reference 2 - Quick A.J. et al., Influence of acetylsalicylic acid and salicylamide on the coagulation of blood, J. Pharmacol Exp. Ther. T960; 128:95-98.

Reference 3 - Weiss H.J., e al., The effect of salicylates on the hemostatic properties of platlets in man, J. Clin. Inves. 1968; 47:2169-2180.

Reference 4 - Miners J.O., Drug interactions involving aspirin and Salicylic acid, Clin. Pharmacokinet. 17(5), 1989, 327-344.

Reference 5 - McInnes G.T., Brodie M.J., Drug interactions that Matter: A Critical Reappraisal, Drugs 36, 1968, 83-l 10.

Reference 6 - Goldenberg M.M., Honkomp L.J., Burrous S.E., Castellion A.W., Protective effect of Pepto-Bismol liquid on the gastric mucosa of rates. Gastroenterology, 1975,69:636-640.

Reference 7 - Goldenberg M.M., Honkomp L.J., Castellion W.W., et al. Prevention by bismuth subsalicylate of gastric mucosal lesions in response to noxious stimuli in rats. Pharmacol. Res. Commun., 1978, 10:13-20.

Reference 8 - Covarrubia, J., A study of the effect of bismuth subsalicylate in preventing blood loss in children with juvenile rheumatoid arthritis treated with aspirin. Project No. 75305-477-73-03-339. Norwich Pharmacal Co., 1976.

Reference 9 - Balm T.K., Maximum-strength Pepto-Bismol crossover bioavailability study. Study # PB-118. Procter & Gamble. 1987.

Reference 10 - Report of Scientific Advisory Group meeting on bismuth subsalicylate pediatric dosing for the treatment of acute diarrhea. Procter & Gamble. 1991.

Reference 11 - Lukacovic M.F., Watters K.J., Bioavailability study with Pentagastrin - Pepto-Bismol with simethicone. PBDB # 14. Procter & Gamble. 1992.

Reference 12 - Lukacovic, M.F., Watters, K.J., Gastric lesion study- Pepto-Bismol with simethicone. EtOH Study - ANTR # 53, Procter & Gamble. 1991.

Volume 23

Appendix 1 - Home Performance Test Report PD # 0390-54 Consumer Definition of Stomach Discomfort Symptoms, continued

Appendix 2 - Summary Report PD # 1083-53, G.I. Symptom Mapping Research

Volume 24

Appendix 3 - Symptom Screening Study for Illness Diary Report MRD # 83274, continued

Volume 25

Appendix 4 - Home Performance Test Report PD # 0292-07 Stomach Discomfort Indices Children Ages 3 - 12

Appendix 5 - Synopsis results of in vitro Foam Reducing Capacity; Laboratory Notebook HH-0736 Results